A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment

NCT07708181 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Gout Arthritis

Interventions

DRUG: SSGJ-613 100 mg Q12W
DRUG: SSGJ-613 200 mg Q12W
DRUG: SSGJ-613 100 mg Q4W
DRUG: Colchicine 0.5 mg

Sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.